

PATENT

Attorney Docket No.: 082368-001500US
Client Ref. No.: E1-A0305Y1P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ITO and SAITO

Application No.: 10/518,472

Filed: October 4, 2005

For: PRIMARY CULTURED
ADIPOCYTES FOR GENE THERAPY

Customer No.: 20350

Confirmation No. 8056

Examiner: Sajjadi, Fereydoun Ghobt

Technology Center/Art Unit: 1633

DECLARATION UNDER
37 C.F.R. § 1.132 OF
MASAYUKI ASO

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. I am presently the President & CEO of CellGenTech., Inc. located on East Wing Shinko music plaza 2F, 2-1, Kanda Ogawamachi, Chiyoda-ku, Tokyo, Japan 101-0052. I graduated from Hokkaido University Faculty of Pharmaceutical Science 1981. I worked as the Product Manager for Bioproducts at Eisai Co., Ltd. From 1981-2001 and as Director of Clinical Development for hepatocyte growth factor ("HGF") gene therapy and NF κ B decoy oligonucleotides at AnGes MG, Inc. from 2001-2004. I have been working as the President & CEO of CellGenTech., Inc. since 2004. CellGenTech is currently conducting research and development with gene-transfected human adipocytes for therapy of intractable diseases. Additionally, I have worked as an adjunct instructor relating to R&D of Biotechnology based drug at the requests of Chiba University and Doshisha University in Japan from 2007.